Literature DB >> 32923159

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer.

Oliver Kepp1,2, Laurence Zitvogel3,4,5,6, Guido Kroemer1,2,6,7,8.   

Abstract

Lurbinectedin is a DNA-binding inhibitor of transcription that potently induces immunogenic cell death (ICD). In June 2020, the Federal Drug Administration (FDA) approved lurbinectedin for the salvage treatment of small-cell lung cancer that has relapsed from platinum compound-based first-line chemotherapy. Thus, the clinical activity of lurbinectedin may originate, at least in part, from the induction of ICD.
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  Transcription inhibitor; anticancer immunity; immune checkpoint blockade; immunotherapy

Mesh：

Substances：

Year:  2020        PMID： 32923159      PMCID： PMC7458590          DOI： 10.1080/2162402X.2020.1795995

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  13 in total

1.  Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.

Authors:  Gema Santamaría Nuñez; Carlos Mario Genes Robles; Christophe Giraudon; Juan Fernando Martínez-Leal; Emmanuel Compe; Frédéric Coin; Pablo Aviles; Carlos María Galmarini; Jean-Marc Egly
Journal:  Mol Cancer Ther       Date:  2016-09-14       Impact factor: 6.261

2.  Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Authors:  Erika Vacchelli; Yuting Ma; Elisa E Baracco; Antonella Sistigu; David P Enot; Federico Pietrocola; Heng Yang; Sandy Adjemian; Kariman Chaba; Michaela Semeraro; Michele Signore; Adele De Ninno; Valeria Lucarini; Francesca Peschiaroli; Luca Businaro; Annamaria Gerardino; Gwenola Manic; Thomas Ulas; Patrick Günther; Joachim L Schultze; Oliver Kepp; Gautier Stoll; Céline Lefebvre; Claire Mulot; Francesca Castoldi; Sylvie Rusakiewicz; Sylvain Ladoire; Lionel Apetoh; José Manuel Bravo-San Pedro; Monica Lucattelli; Cécile Delarasse; Valérie Boige; Michel Ducreux; Suzette Delaloge; Christophe Borg; Fabrice André; Giovanna Schiavoni; Ilio Vitale; Pierre Laurent-Puig; Fabrizio Mattei; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2015-10-29       Impact factor: 47.728

Review 3.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

4.  Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.

Authors:  Heng Yang; Yuting Ma; Guo Chen; Heng Zhou; Takahiro Yamazaki; Christophe Klein; Federico Pietrocola; Erika Vacchelli; Sylvie Souquere; Allan Sauvat; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

5.  Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.

Authors:  Wei Xie; Sabrina Forveille; Kristina Iribarren; Allan Sauvat; Laura Senovilla; Yan Wang; Juliette Humeau; Maria Perez-Lanzon; Heng Zhou; Juan F Martínez-Leal; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2019-09-05       Impact factor: 8.110

6.  eIF2α phosphorylation is pathognomonic for immunogenic cell death.

Authors:  Lucillia Bezu; Allan Sauvat; Juliette Humeau; Lígia C Gomes-da-Silva; Kristina Iribarren; Sabrina Forveille; Pauline Garcia; Liwei Zhao; Peng Liu; Laurence Zitvogel; Laura Senovilla; Oliver Kepp; Guido Kroemer
Journal:  Cell Death Differ       Date:  2018-01-22       Impact factor: 15.828

7.  Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

Authors:  Mickaël Michaud; Isabelle Martins; Abdul Qader Sukkurwala; Sandy Adjemian; Yuting Ma; Patrizia Pellegatti; Shensi Shen; Oliver Kepp; Marie Scoazec; Grégoire Mignot; Santiago Rello-Varona; Maximilien Tailler; Laurie Menger; Erika Vacchelli; Lorenzo Galluzzi; François Ghiringhelli; Francesco di Virgilio; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2011-12-16       Impact factor: 47.728

8.  Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Authors:  José Trigo; Vivek Subbiah; Benjamin Besse; Victor Moreno; Rafael López; María Angeles Sala; Solange Peters; Santiago Ponce; Cristian Fernández; Vicente Alfaro; Javier Gómez; Carmen Kahatt; Ali Zeaiter; Khalil Zaman; Valentina Boni; Jennifer Arrondeau; Maite Martínez; Jean-Pierre Delord; Ahmad Awada; Rebecca Kristeleit; Maria Eugenia Olmedo; Luciano Wannesson; Javier Valdivia; María Jesús Rubio; Antonio Anton; John Sarantopoulos; Sant P Chawla; Joaquín Mosquera-Martinez; Manolo D'Arcangelo; Armando Santoro; Victor M Villalobos; Jacob Sands; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2020-03-27       Impact factor: 41.316

9.  Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress.

Authors:  Juliette Humeau; Allan Sauvat; Giulia Cerrato; Wei Xie; Friedemann Loos; Francesca Iannantuoni; Lucillia Bezu; Sarah Lévesque; Juliette Paillet; Jonathan Pol; Marion Leduc; Laurence Zitvogel; Hugues de Thé; Oliver Kepp; Guido Kroemer
Journal:  EMBO Mol Med       Date:  2020-04-23       Impact factor: 12.137

Review 10.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Sarah Warren; Sandy Adjemian; Patrizia Agostinis; Aitziber Buqué Martinez; Timothy A Chan; George Coukos; Sandra Demaria; Eric Deutsch; Dobrin Draganov; Richard L Edelson; Silvia C Formenti; Jitka Fucikova; Lucia Gabriele; Udo S Gaipl; Sofia R Gameiro; Abhishek D Garg; Encouse Golden; Jian Han; Kevin J Harrington; Akseli Hemminki; James W Hodge; Dewan Md Sakib Hossain; Tim Illidge; Michael Karin; Howard L Kaufman; Oliver Kepp; Guido Kroemer; Juan Jose Lasarte; Sherene Loi; Michael T Lotze; Gwenola Manic; Taha Merghoub; Alan A Melcher; Karen L Mossman; Felipe Prosper; Øystein Rekdal; Maria Rescigno; Chiara Riganti; Antonella Sistigu; Mark J Smyth; Radek Spisek; John Stagg; Bryan E Strauss; Daolin Tang; Kazuki Tatsuno; Stefaan W van Gool; Peter Vandenabeele; Takahiro Yamazaki; Dmitriy Zamarin; Laurence Zitvogel; Alessandra Cesano; Francesco M Marincola
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751
View more
  8 in total

Review 1.  Immunogenic cell stress and death.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Claudia Galassi; Laurence Zitvogel
Journal:  Nat Immunol       Date:  2022-02-10       Impact factor: 25.606

Review 2.  Anticancer Activities of Marine-Derived Phenolic Compounds and Their Derivatives.

Authors:  Dario Matulja; Filip Vranješević; Maria Kolympadi Markovic; Sandra Kraljević Pavelić; Dean Marković
Journal:  Molecules       Date:  2022-02-21       Impact factor: 4.411

Review 3.  Beneficial autoimmunity improves cancer prognosis.

Authors:  Laurence Zitvogel; Claude Perreault; Olivera J Finn; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2021-05-11       Impact factor: 65.011

Review 4.  Cardiac Glycosides as Immune System Modulators.

Authors:  Jan Škubník; Vladimíra Pavlíčková; Silvie Rimpelová
Journal:  Biomolecules       Date:  2021-04-29

5.  Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade.

Authors:  Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2021-11-02       Impact factor: 7.723

6.  Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.

Authors:  Federico Costanzo; Marta Martínez Diez; Gema Santamaría Nuñez; Juan Ignacio Díaz-Hernandéz; Carlos Mario Genes Robles; Javier Díez Pérez; Emmanuel Compe; Romeo Ricci; Tsai-Kun Li; Frédéric Coin; Juan Fernando Martínez Leal; Eva Maria Garrido-Martin; Jean Marc Egly
Journal:  EMBO Mol Med       Date:  2022-03-09       Impact factor: 12.137

7.  PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.

Authors:  Peng Liu; Jianzhou Chen; Liwei Zhao; Antoine Hollebecque; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2022-06-24       Impact factor: 7.723

8.  Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma.

Authors:  Xingxing Gao; Hechen Huang; Caixu Pan; Zhibin Mei; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.